Finally, the explorative plasma analysis showed that protein modifications recorded at different time points respect to the basal concentrations, are not correlated with the efficacy of treatment, even for those proteins that shown a significant change (decrease or increase) in the whole population.
From Tables 1 and 2, it appears that basal CH2FH4 concentrations were not detectable in 5/6 homozygous wt (C/C) 677 genotype, whereas detectable concentrations were observed in 7/13 mut (T/T and C/T) 677 genotype.
Basal GLP-1 concentrations were not affected by mAEA, AM251 or vehicle controls.
Basal plasma oxytocin concentrations were not the same in the groups of weaned pups from different breeding colonies (ANOVA: F3,41 = 7.09, p < 0.001).
Although mean basal plasma glucose concentrations were not significantly different between lean and obese subjects, mean plasma insulin concentration was threefold higher in the obese group than in the lean group.
Basal plasma glucose and insulin concentrations were not different between men and women (Table 3).
In the human insulin experiment (HI) and the insulin detemir experiment (D) basal plasma insulin concentration were not different from S (HI 48±6 pM, p = 0.91; D 57±10 pM, p = 0.16).
Therefore, our findings suggest that elevated basal plasma FFA, IL-6, hsCRP, and leptin concentrations are not necessarily related to the type 2 diabetic state.
Although relative to the lean group the obese group demonstrated evidence of insulin-resistant liver and skeletal muscle glucose metabolism and adipose tissue fatty acid metabolism during the HECP, basal glucose concentration was not significantly different between the two groups.
The basal cortisol concentration was not significantly related to mortality one week and one month after admission, or CPC score, but the ACTH and ADH concentrations were significantly related to mortality one week and one month after admission, and the CPC score (Table 2).
